Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

71%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

1(14.3%)

Phase 1

1(14.3%)

Phase 4

1(14.3%)

7Total

Phase 3(4)

Phase 2(1)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02491437Phase 3Completed

A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)

Role: collaborator

NCT02596321Phase 3Completed

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma

Role: collaborator

NCT03195387Phase 1Withdrawn

Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model

Role: collaborator

NCT02415959Phase 2Completed

Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Role: collaborator

NCT02200029Phase 3Completed

Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption

Role: collaborator

NCT02009410Phase 4Withdrawn

A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2